Birge Ozer, Bakır Mehmet Sait, Karadag Ceyda, Dinc Can, Doğan Selen, Tuncer Hasan Aykut, Simsek Tayup
Akdeniz University, Department of Gynecology Obstetrics, Division of Gynecologic Oncology Antalya, Turkey.
Am J Transl Res. 2021 Jul 15;13(7):8438-8449. eCollection 2021.
In this study, we aimed to compare the clinical and pathological results of borderline ovarian tumor cases that were operated on in our clinic within the last 15 years and to investigate the factors affecting recurrence.
The archived files of the patients with borderline ovarian tumors, who had been operated on at the Akdeniz University Medical Faculty Gynecological Oncology Unit between 2006 and 2020 were retrospectively reviewed. A total of 48 cases were identified and included in the study. Oncological results affecting relapse were evaluated using univariate and multivariate analysis models. Disease-free survival was assessed using the Kaplan-Meier method.
The median follow-up period of the 48 patients included in our study was 51.5 months and while the shortest follow-up was 2 months, the longest follow-up period was 164 months. The mean age of the patients was 47.6 ± 12.5 years, and the mean BMI was found to be 27.2 ± 3.7. Of the patients, 19 (39.6%) were post-menopausal, and when all stages were included, the 10-year progression free survival (PFS) was 65%, while the 10-year overall survival (OS) was 96.6%. It was observed that 8 (16.6%) patients encountered recurrence during their follow-up. The multivariate analysis of significance found for the operation type, adjuvant chemotherapy and micro-invasion in the univariate analysis of clinical pathological characteristics with regard to recurrence, fertility-sparing surgery and micro-invasion were determined to have a significant difference in recurrence (p: 0,016, p: 0,048).
Borderline ovarian tumors are especially seen in young patients and although their clinical prognosis is very good, a significant difference was found in recurrence in patients who had undergone fertility-sparing surgery, in whom the micro-invasion was positive and in those receiving adjuvant chemotherapy, and disease-free survival was shorter in these patients and close follow-up of these patients is recommended.
在本研究中,我们旨在比较过去15年在我们诊所接受手术的卵巢交界性肿瘤病例的临床和病理结果,并研究影响复发的因素。
回顾性分析2006年至2020年在阿克德尼兹大学医学院妇科肿瘤病房接受手术的卵巢交界性肿瘤患者的存档文件。共确定48例病例并纳入研究。使用单变量和多变量分析模型评估影响复发的肿瘤学结果。采用Kaplan-Meier法评估无病生存期。
纳入本研究的48例患者的中位随访期为51.5个月,最短随访期为2个月,最长随访期为164个月。患者的平均年龄为47.6±12.5岁,平均BMI为27.2±3.7。其中19例(39.6%)为绝经后患者,当包括所有分期时,10年无进展生存率(PFS)为65%,10年总生存率(OS)为96.6%。观察到8例(16.6%)患者在随访期间出现复发。在关于复发的临床病理特征单变量分析中,对手术类型、辅助化疗和微浸润有统计学意义的多变量分析发现,保留生育功能手术和微浸润在复发方面有显著差异(p:0.016,p:0.048)。
卵巢交界性肿瘤尤其多见于年轻患者,尽管其临床预后非常好,但在接受保留生育功能手术、微浸润阳性和接受辅助化疗的患者中,复发存在显著差异,这些患者的无病生存期较短,建议对这些患者进行密切随访。